[
serum institute of india news
]Latest from serum institute of india
Pune-based Serum Institute to soon start Phase I & II trials of dengue vaccine in India
The Phase 1 and Phase 2 study of Dengusiil in India will be conducted on 45 adults of 18 years and above and 75 children of 2 years of age and above and less than (<) 18 years of age
Updated on Nov 27, 2023 05:08 AM IST
Vicky Pathare
Serum Institute founder Cyrus Poonawalla suffers cardiac arrest, undergoes angioplasty
Cyrus Poonawalla, chairman of Serum Institute of India, suffered a mild cardiac arrest and underwent angioplasty. He is recovering and will be discharged soon.
Updated on Nov 17, 2023 10:37 PM IST
Vicky Pathare
Serum’s Cervavac vaccine for cervical cancer now in pvt hosps
Cervavac vaccine to fight cervical cancer has been developed and manufactured by the Pune-based Serum Institute of India (SII)
Updated on Jul 18, 2023 12:54 AM IST
Vicky Pathare
SII’s multivalent meningococcal meningitis vaccine gets WHO prequalification
It is also the only vaccine that prevents meningitis caused by meningococcal group X, a pathogen increasingly implicated in meningitis outbreaks in Africa
Updated on Jul 12, 2023 06:01 PM IST
RIL tops list of Indian companies, Serum Institute first among unlisted: Report
The Top 10 companies in India hold ₹71.5 lakh crore, accounting for 37% of GDP. 7 of them are headquartered in Mumbai. Here is the list:
Published on Jun 20, 2023 05:58 PM IST
HC restrains 2 influencers from posting defamatory content against SII, Covishield
The Bombay High Court has restrained two social media influencers from posting defamatory content about Serum Institute of India, its CEO and their Covishield product in an interim application filed by SII in a defamation suit against the influencers. The court directed Yohan Tengra and Ambar Kori to remove the content from Twitter and YouTube. The SII claims the content posted by the duo about multiple deaths being due to the side effects of the vaccine was not only targeted at SII but also its CEO, and sought directions to Twitter and YouTube to take down defamatory content.
Updated on Jun 06, 2023 01:03 AM IST
Bombay HC restrains activists from posting defamatory content on SII, Covishield
The order was passed in an interim application filed by SII in a defamation suit seeking ₹100 crore in damages from social media influencers Yohan Tengra and Ambar Kori for allegedly posting objectionable content regarding Covishield
Updated on Jun 05, 2023 03:28 PM IST
ED attaches Zavaray Soli Poonawalla’s assets worth ₹41.64 crore in Worli
Enforcement Directorate seizes properties worth INR 41.64 crore belonging to Zavaray Soli Poonawalla and family over foreign exchange violation probe linked to Panama Papers.
Updated on May 09, 2023 12:50 AM IST
Abhishek Sharan, Mumbai
‘Fema violation’ case: ED seizes ₹41.64cr assets of Pune bizman
The agency alleged that Zavareh Soli Poonawalla and his family members were accused of misuse of the Liberalised Remittance Scheme under the provisions of the Foreign Exchange Management Act.
Updated on May 09, 2023 12:34 AM IST
HT Correspondent, New Delhi
UK Investment Min inaugurates British Trade office in Pune
According to a press release released by the British Deputy High Commission, India remains a priority market for the UK
Updated on Apr 28, 2023 11:29 PM IST
Serum Institute of India to produce 5mn Covishield doses in two months
SII has made available five to six million Covovax doses even as the demand for it is still almost zero. We will produce the same amount of Covishield doses in the next two to three months, said Adar Poonawalla
Updated on Apr 22, 2023 11:01 PM IST
WATCH: SII chief Adar Poonawalla on vaccine availability, current Covid strain
SII chief Adar Poonawalla on Saturday said that the current Covid strain is not severe and the company has produced five to six million doses of Covovax.
Published on Apr 22, 2023 03:08 PM IST
India's Serum Institute resumes Covishield production as Covid cases surge
SII CEO Adar Poonawalla says Covishield manufacturing has resumed, 6M Covovax booster doses ready, and manufacturers are ready but no demand yet.
Published on Apr 12, 2023 05:38 PM IST
PTI | | Posted by Animesh Chaturvedi
Serum institute seeks to add Covovax on CoWIN portal as booster dose for adults
Last month, COVID-19 Working Group also recommended to the health ministry inclusion of Covovax on the CoWIN portal as a heterologous booster dose for adults.
Published on Apr 03, 2023 08:10 PM IST
PTI |
Oxford, Serum initiative: Anti-malaria vaccine’s Phase 3 trials conclude
The R21 malaria vaccine, which is also known as Matrix-M, was designed at the Jenner Institute, University of Oxford, which collaborated with SII in 2020 to manufacture and develop the jab for large-scale supply.
Published on Dec 06, 2022 08:33 AM IST
Soumya Pillai, New Delhi
Serum Institute Whatsapp duping case: Seven held from various states
As per the First Information Report registered with Bundgarden police station in the second week of September, the accused had used Poonawalla's image in a Whatsapp account and sent messages about money transfer to Satish Deshpande, one of the directors of the firm.
Published on Nov 25, 2022 07:32 PM IST
PTI |
SII's Adar Poonawalla expects Omicron-specific vaccine in 6 months: Report
Adar Poonawalla's statement came even as the UK became the first country to authorise an updated version of Moderna's Covid-19 vaccine that includes protection against the Omicron variant.
Published on Aug 15, 2022 11:36 PM IST
HT News Desk, New Delhi
Monkeypox: As India sees rise in cases, what Adar Poonawalla said about vaccine
India has so far reported eight cases of monkeypox, of which five have been from Kerala and three from Delhi. Of the five patients in Kerala, one succumbed to the disease on July 30, making it India's first monkeypox fatality.
Published on Aug 02, 2022 05:41 PM IST
Written by Sharangee Dutta | Edited by Aniruddha Dhar, New Delhi
Serum institute seeks government nod to export Covovax to the US
SII manufactures Covovax under a license from the vaccine’s developer, US-based Novavax. The export version of the vaccine is called Nuvaxovid and has been dispatched to New Zealand, Netherlands, Australia and Indonesia, where a total of at least 100 million doses have been sent.
Published on Jul 01, 2022 03:16 AM IST
Rhythma Kaul, New Delhi
Govt panel recommends market authorisation for Serum's cervical cancer vaccine
Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.
Published on Jun 15, 2022 10:37 PM IST
PTI |
Covovax gets govt nod for 12-18 age group at private centres
On April 29, the National Technical Advisory Group on Immunisation (NTAGI)--the government’s technical panel--recommended inclusion of Covovax in the vaccination programme for children aged 12 and above.
Published on May 03, 2022 11:37 PM IST
'Covovax now available for children in India', says Adar Poonawalla, hails Modi
Serum Institute of India (SII) director for government and regulatory affairs Prakash Kumar Singh had written to the Centre recently requesting for Covovax's inclusion in the immunisation drive for children aged 12 to 17 years.
Updated on May 10, 2022 07:57 PM IST
HT News Desk, New Delhi
Made in India Covid vaccines better than Pfizer, Moderna: SII's Adar Poonawalla
Speaking to ANI, Poonawalla said, "The Covid-19 vaccines which have been made in India are providing more protection against the disease than mRNA vaccines like Pfizer and Moderna."
Published on Apr 13, 2022 04:22 PM IST
ANI |
Covishield booster shots to be priced at ₹600 plus taxes: Adar Poonawalla
Covovax - which has not been formally announced as a booster shot, will be priced around ₹900 plus taxes, once approved. The vaccine is currently being used to inoculate adults and those in the 12-17 age group in emergency situations.
Updated on Apr 08, 2022 06:54 PM IST
hindustantimes.com | Written by Sharangee Dutta, New Delhi
Can’t disclose data on trials: Vaccine makers to Supreme Court
Submitting its reply to Puliyel’s petition in November last, the central drugs standard control organization (CDSCO) said that entertaining such a petition would harm public interest.
Updated on Mar 23, 2022 05:04 AM IST
Give full authorisation to Covishield: Serum Institute of India
Serum Institute of India locally manufactures the Oxford-AstraZeneca Covid-19 vaccine under the brand name Covishield.
Updated on Dec 31, 2021 11:07 PM IST
Serum Institute of India applies for full approval of Covishield Covid vaccine
Serum Institute, which produces AstraZeneca's Covid-19 vaccine under the brand name Covishield, has supplied more than 1.25 billion doses of the shot in India.
Published on Dec 31, 2021 01:48 PM IST
Reuters | , Bengaluru
Covovax gets WHO’s nod for emergency use
SII has the license to produce over two billion doses of the vaccine
Published on Dec 18, 2021 02:14 AM IST
HT Correspondent, Hindustan Times, New Delhi
Vaccine maker SII pledges $66 million to Oxford University
The investment was made through the Indian company's Serum Life Sciences unit, Oxford University said on Wednesday.
Published on Dec 15, 2021 05:50 AM IST
Reuters |
Omicron: Will India allow booster dose? Here's what central expert panel said
The Pune-based SII had earlier on December 1 requested the DCGI to authorise Covishield as a booster dose, citing the emergence of new coronavirus variants in the country and an adequate stock of vaccines to tackle that growing concern.
Published on Dec 11, 2021 07:53 AM IST
Written by Joydeep Bose | Edited by Meenakshi Ray, Hindustan Times, New Delhi
